By creating medicines to control gene expression, we aim to make a profound difference in the lives of patients and their families.
At the heart of all our efforts at Syros is our dedication to advancing medicines that provide a profound benefit for patients with difficult-to-treat diseases.
We have a singular focus on developing and delivering new standards of care for the frontline treatment of hematologic malignancies. We currently have programs in clinical development for genomically defined patients with MDS, AML and APL. We are exploring out-licensing opportunities for our SY-5609 clinical program, an oral reversible CDK7 with best-in-class selectivity and potency, enabling broad development potential. We are also exploring out-licensing opportunities for our preclinical oncology programs, consisting of potential first-in-class and best-in-class assets.
Interested in participating in a clinical trial?